Researchers started a phase II trial to evaluate the impact of tazemetostat, an EZH2 inhibitor, in relapsed PM patients with inactivated BAP1 since mesothelioma cells with inactivated BAP1 are susceptible to EZH2 pharmacologic inhibition. This evidence concerns the gene EZH2 and mesothelioma.